Therapixel announces launch of prospective study on the utility of Artificial Intelligence (AI) as part of second reading breast cancer screening mammograms
The first French prospective clinical study to evaluate the…
Therapixel releases a new version of MammoScreen® that leverages prior exams for better accuracy
For the first time, an AI-based decision support software…
Therapixel announces close of 15 M€ series B financing to deploy MammoScreen® 2D/3D
The Company will accelerate the commercial deployment of…
Therapixel receives FDA clearance for use of its AI-based breast cancer screening software MammoScreen® on Digital Breast Tomosynthesis
AI-powered reading aid for screening 2D & 3D mammography…
Therapixel will be showcasing MammoScreen™ at the virtual ECR 2021
Stop by our booth to learn more about our FDA-cleared and…
Therapixel receives the CE mark for its Artificial Intelligence-based software (AI) MammoScreen™
This cutting-edge technology assists radiologists in the…
Therapixel and RAD-AID International Announce Breast Imaging AI Collaboration for Global Health
The collaboration donates and supports AI for making breast…
Therapixel participates in the Journées Francophones de Radiologie 2020
Experience the Award-winning MammoScreen™ at our virtual…
Therapixel receives FDA 510(k) clearance for MammoScreen™
AI-powered reading aid for screening mammography improves…